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Objective: Melanin-concentrating hormone (MCH) plays a key role in regulating energy balance. MCH acts via its receptor MCHR1, and MCHR1
deletion increases energy expenditure and locomotor activity, which is associated with a hyperdopaminergic state. Since MCHR1 expression is
widespread, the neurons supporting the effects of MCH on energy expenditure are not clearly deﬁned. There is a high density of MCHR1 neurons
in the striatum, and these neurons are known to be GABAergic. We thus determined if MCH acts via this GABAergic neurocircuit to mediate energy
balance.
Methods: We generated a Mchr1-ﬂox mouse and crossed it with the Vgat-cre mouse to assess if MCHR1 deletion from GABAergic neurons
expressing the vesicular GABA transporter (vGAT) in female Vgat-Mchr1-KO mice resulted in lower body weights or increased energy expenditure.
Additionally, we determined if MCHR1-expressing neurons within the accumbens form part of the neural circuit underlying MCH-mediated energy
balance by delivering an adeno-associated virus expressing Cre recombinase to the accumbens nucleus of Mchr1-ﬂox mice. To evaluate if a
dysregulated dopaminergic tone leads to their hyperactivity, we determined if the dopamine reuptake blocker GBR12909 prolonged the drug-
induced locomotor activity in Vgat-Mchr1-KO mice. Furthermore, we also performed amperometry recordings to test whether MCHR1 dele-
tion increases dopamine output within the accumbens and whether MCH can suppress dopamine release.
Results: Vgat-Mchr1-KO mice have lower body weight, increased energy expenditure, and increased locomotor activity. Similarly, restricting
MCHR1 deletion to the accumbens nucleus also increased locomotor activity. Vgat-Mchr1-KO mice show increased and prolonged sensitivity to
GBR12909-induced locomotor activity, and amperometry recordings revealed that GBR12909 elevated accumbens dopamine levels to twice that
of controls, thus MCHR1 deletion may lead to a hyperdopaminergic state that mediates their observed hyperactivity. Consistent with the inhibitory
effect of MCH, we found that MCH acutely suppresses dopamine release within the accumbens.
Conclusions: As with established models of systemic MCH or MCHR1 deletion, we found that MCHR1 deletion from GABAergic neurons,
speciﬁcally those within the accumbens nucleus, also led to increased locomotor activity. A hyperdopaminergic state underlies this increased
locomotor activity, and is consistent with our ﬁnding that MCH signaling within the accumbens nucleus suppresses dopamine release. In effect,
MCHR1 deletion may disinhibit dopamine release leading to the observed hyperactivity.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Melanin-concentrating hormone (MCH) is produced in the lateral hy-
pothalamus [1] and has emerged as a critical player in the regulation of
central energy balance [2,3]. Acute MCH administration stimulates
food intake [4], and chronic MCH infusion increases body weight gain
[5]; thus MCH increases orexigenic drive and promotes positive energy
balance. Furthermore, MCH gene expression is upregulated in mouse
models of obesity like the leptin-deﬁcient ob/ob mouse [4], and MCH-
overexpressing mice are more prone to diet-induced obesity [6]. By
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(Mch-KO) mice are lean and have increased energy expenditure and
locomotor activity [8,9]. Consistent with this, deletion of MCH in ob/ob
mice attenuates their obesity [10]. Mch-KO mice also display pro-
longed hyperactivity when treated with a dopamine reuptake blocker
and are more susceptible to amphetamine sensitization [11]. More-
over, amperometry recordings from the striatum show higher dopa-
mine output from fresh Mch-KO brain slices [11]. These ﬁndings
indicate that a hyperdopaminergic state in the striatum mediates the
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In rodents, MCH acts exclusively via the MCH receptor MCHR1, which
is a Gi-protein coupled receptor [12e14]. Consistent with the effects of
MCH deletion, MCHR1 knockout (Mchr1-KO) mice are also lean,
resistant to diet-induced obesity, have increased energy expenditure,
and exhibit pronounced hyperactivity [15,16]. As such, the leanness
observed in Mch-KO and Mchr1-KO mice is largely attributed to their
increased energy expenditure and/or hyperactivity. Furthermore, both
MCH and MCHR1 deletion increase amphetamine-mediated hyperac-
tivity [17e19], which is also recapitulated following the ablation of
MCH neurons in adult mice [20], thereby implicating MCH as a regu-
lator of the dopaminergic system.
MCH nerve terminals may regulate dopamine release in the striatum
[21], a key integrative region for motor control. It has been shown that
MCH infusion into the ventral striatum may also stimulate food intake
[22,23]. Indeed, the most prominent expression of Mchr1 mRNA is in
the striatum, which includes the caudate putamen and accumbens
nucleus in the dorsal and ventral striatum, respectively [24]. These
regions are almost entirely comprised of GABAergic medium spiny
neurons or interneurons [25]. In aggregate, these data suggest that
GABAergic neurons may mediate some actions of MCH, including
dopamine-mediated locomotor activity.
To assess the actions of MCH on GABAergic neurons that effect
energy expenditure and locomotor activity, we deleted MCHR1 from
neurons that express the vesicular GABA transporter, vGAT, by
generating the Mchr1-ﬂox mouse and crossing it to the Vgat-cre
mouse to enable cre-mediated deletion of MCHR1 from GABAergic
neurons. Mice with the loss of MCHR1 in vGAT neurons were lean
and display robust baseline locomotor activity and heightened
sensitivity to dopamine-mediated hyperactivity. Cre-mediated dele-
tion of MCHR1 from the accumbens nucleus using an adeno-
associated virus to express Cre recombinase in Mchr1-ﬂox mice
also increased locomotor activity. Striatal brain slices following
MCHR1 deletion have elevated dopaminergic levels when treated
with a dopamine reuptake blocker during amperometry recordings.
Moreover, MCH directly inhibits dopamine release to the accumbens
nucleus in these striatal brain slices; an effect that is abolished by the
loss of MCHR1 in vGAT neurons. Taken together, these ﬁndings
indicate that MCH regulates locomotor activity via GABAergic neurons
in the accumbens nucleus, and that it does so in part by inhibiting
dopamine release.
2. MATERIALS AND METHODS
2.1. Animals
Experiments were performed in female mice housed under a 12 h light,
12 h dark cycle, at 22  2 C, and provided with ad libitum access to
water and standard lab chow (3.23 kcal/g, Formulab Diet 5008,
LabDiet, St. Louis, MO). All procedures adhere to the National Institute
of Health Guidelines for the Care and Use of Animals and were
approved by the Institutional Animal Care and Use Committee at the
Beth Israel Deaconess Medical Center (Boston, MA).
2.1.1. Generation of Mchr1-ﬂox mouse
We generated the Mchr1-ﬂox mouse by designing a targeting vector
that inserted loxP sites ﬂanking exon2 of the Mchr1 gene. A 2.7 kb
genomic fragment containing exon2 was PCR-ampliﬁed from murine
genomic DNA and cloned at a SmaI site 50 of a neomycin resistance
cassette ﬂanked by Frt sites, and 30 of a loxP site previously inserted
in the pBACe3.6 cloning vector (Sanger Institute, Hinxton, United
Kingdom). A 4.95 kb genomic fragment containing exon1 of theMOLECULAR METABOLISM 29 (2019) 114e123  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comMchr1 gene was inserted at a NotI site immediately 50 of the above
mentioned loxP site. Similarly, a 2.9 kb genomic fragment containing
downstream intron2 sequences was introduced 30 of a second LoxP
site cloned immediately 30 of the Frt-ﬂanked neomycin cassette. The
cloned intronic sequence resided upstream of a diphtheria toxin A
cassette used for selection of the ES cell clones that successfully
underwent 30 homologous recombination. All genomic fragments
were fully Sanger-sequenced after completion of the transgenic
construct. Mice of the F1 generation were bred with Flp-expressing
mice (#003946, Jackson Laboratory, Bar Harbor, ME) in order to
eliminate the neomycin cassette, and one Frt site remained 50 of the
30-most loxP site in intron2.
2.1.2. Generation of Vgat-Mchr1-KO mouse
We crossed our Mchr1-ﬂox mouse with the Vgat-cre mouse
(#016962, Jackson Laboratory) to produce the Vgat-Mchr1-KO
mouse, in which the MCHR1 was deleted from GABAergic neurons
expressing vGAT (Figure 1A). Both Mchr1-ﬂox and Vgat-cre mice
were bred onto the C57/BL6 background (#000664, Jackson Labo-
ratory) for at least eight generations. The Mchr1-ﬂox and Vgat-cre
mouse lines were indistinguishable from their respective wild-type
littermates by body weight, food intake, or locomotor activity
(Supplemental Tables 1 and 2). We chose Vgat-cre mice as the
control group for our experiments due to potential metabolic differ-
ences caused by the expression of Cre recombinase [26].
2.2. Gene expression
2.2.1. In situ hybridization
The Vgat-cre and Vgat-Mchr1-KO mouse brains were perfused and
sliced into ﬁve series of 30 mm coronal sections as previously
described [24]. A [35S]-labeled antisense Mchr1 riboprobe comprising
nucleotide 30e1061 of the rat Mchr1 mRNA was used to detect
MCHR1 mRNA as previously described [24]. In brief, free-ﬂoating brain
sections were pretreated with sodium citrate buffer (pH 6.0, 5 min,
90 C), incubated with the Mchr1 riboprobe for 18 h at 60 C, and then
washed by sequentially increasing the stringency of sodium citrate
buffer exchanges. The brain slices were mounted, dehydrated, and
delipidated before placing in X-ray ﬁlm cassettes with BioMax MR ﬁlm
(Kodak, Rochester, NY) for ﬁve days.
2.2.2. Quantitative RT-PCR analysis
Microdissected brain tissue samples from the caudate putamen,
accumbens nucleus, hippocampus, and cerebellum were ﬂash-frozen
in liquid nitrogen. We ﬁrst isolated RNA from these tissue samples
using the Direct-zol RNA MiniPrep Kit (Zymo Research, Irvine, CA) and
concentrated the resulting RNA solutions via a glycogen-ethanol pre-
cipitation using 20 mg/ml UltraPure Glycogen (Invitrogen, Carlsbad, CA),
as necessary. Total RNA (0.5 mg) was reverse transcribed to synthesize
cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Ger-
mantown, MD). We performed quantitative RT-PCR via SYBR Green
master mix (Applied Biosystems, Foster City, CA) using the 7800HT
thermal cycler (Applied Biosystems). Relative mRNA expression was
calculated via double delta Ct analysis and normalized to expression
levels of the housekeeping gene cyclophilin. Custom primers for
cyclophilin (CypB) and Mchr1 were obtained from Invitrogen (Carlsbad,
CA) using the following sequences: CypB forward, 50-GGTGGA-
GAGCACCAAGACAGA-30; CypB reverse, 50-GCCGGAGTCGACAATGATG-
30; Mchr1 forward, 50-CAATGCCAGCAACATCTCC-30; Mchr1 reverse,
50-ACCAAACACTGAAGGCATGA-30.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 115
Figure 1: Cre-mediated deletion of Mchr1 from GABAergic neurons expressing the vesicular GABA transporter. Vgat-Mchr1-KO mice were generated by crossing the Vgat-
cre mouse to the Mchr1-ﬂox mouse to delete exon2, ﬂanked by loxP sites, of the Mchr1 gene (A). Autoradiographs of 35S-labeled hybridization signal for Mchr1 mRNA in the Vgat-
cre (Bi) and Vgat-Mchr1-KO (Bii) mouse brain tissue demonstrated the absence of 35S-Mchr1 hybridization in GABAergic striatal regions (black solid line), but not glutamatergic
pyramidal layer of the cortex or hippocampus (gray dashed line) (B). qPCR analysis from the striatum, hippocampus, and cerebellum collected from the same mice shows the loss
of Mchr1 mRNA in the striatum of Vgat-Mchr1-KO mice only (C). Ordinary one-way ANOVA: **, p < 0.01; ***, p < 0.001.
Brief Communication2.3. Metabolic and behavioral analysis
2.3.1. Food intake
Food intake was measured by weighing food in the hoppers of
individually-housed mice for either one day or over several days as
indicated.
2.3.2. Body composition
Body composition was determined using EchoMRI (Echo Medical
Systems, Houston, TX) at 12 weeks of age.116 MOLECULAR METABOLISM 29 (2019) 114e123  2019 The Authors. Published by Elsevier GmbH. T2.3.3. Energy expenditure
Energy expenditure was assessed in 12 week old mice by measuring
oxygen consumption (VO2) using the Comprehensive Lab Animal
Monitoring System (Columbus Instruments, Columbus, OH). Mice were
acclimated for two days before two days of active data collection.
2.3.4. Locomotor activity
All mice were habituated to single housing for at least 24 h before
initiating locomotor recordings. We calculated locomotor activity using
the Opto-M3 infrared beam break monitoring system (Columbushis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Instruments, Columbus, OH), where a Multi Device Interface (v1.3)
recorded the number of sequential beam breaks along the x-axis over
a 24-hour period. Stock solutions of GBR12909 (7 mg/ml; Tocris
Bioscience, Bristol, United Kingdom) were prepared using ﬁlter-
sterilized double-distilled water immediately prior to use. We ﬁrst
tested the effects of repeated vehicle injections, which did not enhance
their sensitivity to locomotor activity (data not shown). We then
compared the effect of GBR12909 (20 mg/kg, i.p.) on locomotor ac-
tivity to the effect of the vehicle (sterile water, i.p.), which was
administered 24 h prior to the same mouse. All injections started at
hour 6 of Zeitgeber time and we tracked their locomotor activity for ﬁve
consecutive hours post-injection; this took place over the second half
of the light cycle.
2.4. Stereotaxic injections
Mchr1-ﬂox mice (4e6 week old) were anesthetized with a ketamine
(100 mg/kg)-xylazine (10 mg/kg) mixture and placed in a mouse ste-
reotaxic frame. We bilaterally delivered a total of 800 nl (400 nl per
hemisphere) of an adeno-associated viral vector (University of North
Carolina Gene Therapy Center, Chapel Hill, NC) encoding either Cre
recombinase-mCherry (AAV8-hSyn-CRE-mCherry, 2.8  1012
genomic copies/ml) or mCherry only (AAV8-hSyn-mCherry, 8.0 1012
genomic copies/ml) to the rostral (anteroposterior (AP) þ1.60,
mediolateral (ML) 0.60 and  1.40, dorsoventral (DV) 4.25
and 4.75) and caudal accumbens (AP þ1.20, ML 0.60
and  1.50, DV e4.30 and 4.80) using mouse atlas coordinates
[27]. All mice were returned to their home cage and received bupre-
norphine (0.1 mg/kg, i.p.) analgesia for 24 h post-surgery. We
determined their home cage locomotor activity after viral transfection
and surgery recovery for seven weeks.
After the completion of the experiments, one mouse each from the
control and experimental groups was deeply anesthetized and
sacriﬁced by transcardiac perfusion with saline and 10% formalin for
histological analysis to determine the spread of the virus throughout
the striatum. Brains were sliced into 30 mm coronal sections to
determine native mCherry-ﬂuorescence at the injection site. We
acquired stitched epiﬂuorescence images with a fully motorized
BX61VS microscope (Olympus, Tokyo, Japan) running VS-ASW-FL
software (Olympus), and we viewed and exported the images off-
line using OlyVIA software (Olympus). Brains from remaining mice
were rapidly removed from the skull for quantitative RT-PCR analysis
of Mchr1 mRNA from the caudate putamen and accumbens nucleus,
as described in section 2.2.2.
2.5. Amperometry
Animals were anesthetized with chloral hydrate (400 mg/kg, i.p.) and
transcardially perfused with ice-cold, carbogenated (95% O2, 5%
CO2)-ACSF containing (in mM): 110 choline chloride, 25 NaHCO3, 2.5
KCl, 7 MgCl2, 0.5 CaCl2, 1.25 NaH2PO4, 25 glucose, 11.6 ascorbic
acid, 3.1 pyruvic acid (pH 7.35, 305 mOsm/L). The brain was rapidly
removed from the skull and coronal brain slices (350 mm) were sliced
(4 C), then incubated in the choline-based ACSF for an additional
5 min (37 C). These acute brain slices recovered in a carbogenated
bath ACSF containing (in mM): 124 NaCl, 2.5 KCl, 1.24 NaH2PO4, 1.3
MgCl2, 10 glucose, 26 NaHCO3, 2.5 CaCl2 (300 mOsm/L) for 10 min
(37 C) before resting at room temperature (22 C,>1 h) until used for
recordings.
Each slice (between Bregma þ1.35 mm to þ0.60 mm) was trans-
ferred to the recording chamber and maintained by constant perfusion
of carbogenated bath ACSF at 32 C. A concentric bipolar stimulating
microelectrode (CBBPF100, FHC, Bowdoin, ME) was placed at theMOLECULAR METABOLISM 29 (2019) 114e123  2019 The Authors. Published by Elsevier GmbH. This is an open
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ﬁber electrode (Carbostar-1 E1011-7, 100 mm tip length, Kation Sci-
entiﬁc, Minneapolis, MN) was positioned within 100 mm of the stim-
ulating electrode at approximately 50 mm beneath the tissue surface.
The electrode used in each recording was calibrated with fresh 5 mM
dopamine standards by sampling the current amplitude detected at
one-minute intervals while holding at þ600 mV in order to calculate
the conversion of current amplitude to extracellular dopamine con-
centration. Dopamine (SigmaeAldrich, St. Louis, MO) standard stock
solutions (5 mM) were prepared in 500 mM sodium metabisulﬁte and
stored as frozen aliquots at 20 C.
To evoke dopamine release, we delivered a single 1 ms rectangular
pulse (80 mA) to the stimulating electrode at 5-minute intervals with a
constant current stimulus isolator (World Precision Instruments, Sar-
asota, FL) while applying a constant voltage ofþ600 mV to the carbon
ﬁber tip with a Multiclamp 700B ampliﬁer (Molecular Devices, San
Jose, CA). We sampled the amperometric readings using Clampex 10
software (Molecular Devices) and maintained a stable dopamine
output, where peak amplitudes were within 10% of each other, for at
least 25 min before drug application. Each pharmacological compound
was prepared immediately before use by dilution in carbogenated bath
ACSF, then bath applied to the recording chamber for 15e20 min.
2.6. Statistical analysis
We analyzed amperometry data using Clampﬁt 10.7 software (Mo-
lecular Devices) and all other data sets using Excel (Microsoft Cor-
poration, Redmond, WA). All data are reported as group mean  SEM,
with the number of mice or slices per group included in parentheses
within each ﬁgure. We used Prism 6 (GraphPad, La Jolla, CA) to
determine statistical signiﬁcance for group means using either an
ordinary one-way ANOVA with post-hoc Bonferonni test or an unpaired
Student’s t-test, where appropriate, with *, p< 0.05; **, p< 0.01; and
***, p < 0.001. We also used a repeated measures two-way ANOVA
with post-hoc Bonferonni test to compare entire data sets over time,
with y, p < 0.05 and yy, p < 0.01.
3. RESULTS
3.1. Conditional MCHR1 deletion from GABAergic neurons
produced lean, hyperactive mice
We generated Mchr1-ﬂox mice and mated them to Vgat-cre mice to
delete MCHR1 from GABAergic neurons in Vgat-Mchr1-KO mice
(Figure 1A). Following in situ hybridization, a comparison of autora-
diographic images from Vgat-cre control and Vgat-Mchr1-KO brain
tissue labeled with an isotopic [35S]-Mchr1 riboprobe show a distinct
absence of Mchr1 hybridization in GABAergic regions like the striatum
but not glutamatergic pyramidal neurons throughout the hippocampus
or cortex (Figure 1B). We quantiﬁed the extent of MCHR1 deletion by
RT-qPCR analysis and show a complete loss of Mchr1 mRNA from
Vgat-Mchr1-KO striatal tissue relative to Vgat-cre and Mchr1-ﬂox
controls (Figure 1C). Meanwhile, Mchr1 mRNA expression levels
remain unchanged in the hippocampus, where MCHR1-expressing
neurons are on glutamatergic pyramidal neurons [24,28], or in the
cerebellum, where MCHR1 expression is minimal.
Compared to Vgat-cre controls, adult Vgat-Mchr1-KO mice weighed
10% less (Figure 2A) and had a lower body fat percentage (Figure 2B)
while consuming the same number of calories (12.6 0.7 kcal, n¼ 8;
Vgat-cre: 14.2 0.7 kcal, n¼ 8; p¼ 0.133). MCHR1 deletion in vGAT
neurons increased VO2 consumption (Figure 2C) and Vgat-Mchr1-KO
mice showed a 93% increase in home cage locomotor activity
(Figure 2D). These ﬁndings indicate that cre-mediated deletion ofaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 117
Figure 2: Mchr1 deletion from GABAergic neurons resulted in lean and hyperactive mice with increased dopamine-mediated locomotor activity. At 12 weeks of age,
Vgat-Mchr1-KO (cKO) mice weighed 10% less (A), consistent with lower body fat (B). They also have increased oxygen consumption (C) and home cage locomotor activity (D).
Systemic administration of GBR12909 (GBR, 20 mg/kg, i.p.) in cKO mice produced a longer-lasting increase in home cage locomotor activity (E). Repeated measures two-way
ANOVA: y, p < 0.05 (vs. Vgat-cre; Ci, Di); #, p < 0.05 (vs. Vgat-cre GBR; Ei). Bonferroni multiple comparisons post-test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Di). Ordinary
two-way ANOVA (Eii). Student’s t test: *, p < 0.05; **, p < 0.01 (Aii, B, Cii, Dii).
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Mchr1 from GABAergic neurons produces lean mice that have
increased energy expenditure.
Considering the baseline hyperactivity of Vgat-Mchr1-KO mice, we
next examined how these mice would respond to a paradigm of hy-
peractivity induced by the blockade of dopamine reuptake [11]. Sys-
temic treatment of Vgat-cre and Vgat-Mchr1-KO mice with the
dopamine reuptake inhibitor GBR12909 (20 mg/kg) produced a pro-
nounced and sustained increase in the locomotor activity of all mice
relative to vehicle treatment. Interestingly, conditional MCHR1 deletion
heightened the sensitivity of Vgat-Mchr1-KO mice to GBR12909 and
increased their induced hyperactivity compared to Vgat-cre controls.
GBR12909-mediated ambulation peaked 90 minutes post-injection for
all mice (Figure 2Ei), but this increase was greater in Vgat-Mchr1-KO
mice. The effect of GBR12909 was also longer-lasting in Vgat-Mchr1-
KO mice. Vgat-cre mice returned to baseline ambulation levels within
four hours, while the locomotor activity of Vgat-Mchr1-KO mice
remained sustained and elevated for at least ﬁve hours (Figure 2Ei). In
effect, the cumulative ambulatory count of Vgat-Mchr1-KO mice
treated with GBR12909 was two-fold higher than the treated Vgat-cre
mice (Figure 2Eii). These ﬁndings suggest that a dysregulation of theFigure 3: Deletion of Mchr1 in the accumbens nucleus increased locomotor activit
mCherry ﬂuorescence in the accumbens nucleus of Mchr1-ﬂox mice seven weeks follow
mCherry, Bi) or Cre-mCherry (AAV8-hSyn-Cre-mCherry, Bii). Transfection with Cre-mChe
relative to the caudate putamen (CPu) and increased home cage locomotor activity through
way ANOVA: y, p < 0.05. Bonferroni multiple comparisons post-test: *, p < 0.05; **, p
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displayed by Vgat-Mchr1-KO mice.
3.2. Deletion of MCHR1 from the accumbens nucleus increased
locomotor activity
In order to identify the candidate GABAergic MCHR1 neurons that
contribute to the hyperactivity of Vgat-Mchr1-KO mice, we bilaterally
deleted Mchr1 mRNA from the accumbens nucleus of Mchr1-ﬂox mice
by stereotaxic delivery of an AAV encoding Cre-mCherry. Our viral
delivery conﬁned mCherry expression to the accumbens nucleus
(Figure 3A), and we evaluated Mchr1 expression in the accumbens
nucleus compared to the dorsally-located caudate putamen to verify
the efﬁcacy and speciﬁcity of this cre-mediated deletion. Additionally,
we also injected Mchr1-ﬂox mice with an AAV encoding mCherry only
to control for decreases in Mchr1 levels following AAV delivery.
Mchr1-ﬂox mice transfected with Cre-mCherry showed a 50%
reduction of Mchr1 mRNA in the accumbens nucleus, while Mchr1-ﬂox
mice transfected with mCherry expressed similar Mchr1 mRNA levels
between the accumbens and caudate putamen (Figure 3B). Although
our AAV cre-mediated strategy only produced a partial deletion ofy. Representative epiﬂuorescence photomicrograph (A) illustrating the spread of native
ing stereotaxic delivery of an adeno-associated virus encoding mCherry (AAV8-hSyn-
rry produced a half-fold reduction in Mchr1 gene expression in the accumbens (Acc)
out a 24-hour period (Ci) and in total (Cii). Scale bar, 1 mm. Repeated measures two-
< 0.01 (Ci). Student’s t test: *, p < 0.05 (Bii, Cii).
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Figure 4: Reversible MCH-mediated inhibition of dopamine release in the
accumbens nucleus. Representative traces from an amperometry recording of
dopamine current before (black) and after a 20-minute bath application of 3 mM
GBR12909 (GBR, red) to freshly prepared striatal brain slices from Vgat-cre (Ai) or Vgat-
Mchr1-KO mice (Aii). GBR produced a greater increase in dopamine current amplitude
from the accumbens of Vgat-Mchr1-KO mice (Aiii). Representative amperometric
traces of dopamine current before (Bi), immediately following a 15-minute bath
application of 3 mM MCH (Bii), and after its washout (Biii). MCH elicited a reversible
inhibition of dopamine current in striatal slices from control but not Vgat-Mchr1-KO
mice (Biv). Repeated measures two-way ANOVA: y, p < 0.05; yy, p < 0.01. Bon-
ferroni multiple comparisons post-test: *, p < 0.05; **, p < 0.01.
Brief Communicationaccumbens Mchr1, cre-injected mice displayed a near two-fold in-
crease in total ambulation that is sustained throughout their entire dark
cycle (Figure 3C). There was no differences in their body weight
(mCherry: 25.4  1.3 g, n ¼ 3; Cre-mCherry: 22.6  0.9 g, n ¼ 5;
p¼ 0.116) or daily food intake (mCherry: 11.1 2.0 kcal, n¼ 3; Cre-
mCherry: 10.7  2.2 kcal, n ¼ 5; p ¼ 0.903). This suggested that
MCHR1 neurons within the accumbens nucleus mediate the effects of
MCH on locomotor activity.
3.3. Conditional MCHR1 deletion dysregulates dopamine
transmission in the accumbens nucleus
Since both Mch-KO [11] and Vgat-Mchr1-KO (Figure 2E) mice show an
enhanced sensitivity to dopamine-mediated hyperactivity, we sought
to determine if MCH signaling directly interacts with the dopamine
system of the accumbens nucleus. In order to measure dopamine
release, we performed in vitro amperometry recordings in fresh brain
slices containing the striatum and determined the peak current
amplitude evoked by a stimulating electrode every ﬁve minutes. There
were no differences in the kinetics of the evoked dopamine current
from Vgat-cre and Vgat-Mchr1-KO mice, which had similar rise times
(Vgat-cre: 64.9 11.7 ms, n¼ 5; Vgat-Mchr1-KO: 105.4 19.1 ms,
n¼ 6; p¼ 0.119) and decay times (Vgat-cre: 273.5 42.3 ms; Vgat-
Mchr1-KO: 360.2  46.0 ms; p ¼ 0.206). Bath application of
GBR12909 (3 mM) increased dopamine release within acute brain
slices from both Vgat-Mchr1-KO and Vgat-cre mice. Notably,
GBR12909 elicited a two-fold greater increase in dopamine release
from Vgat-Mchr1-KO striatal slices (Figure 4A), thus conﬁrming that
the loss of MCHR1 signaling increased the sensitivity of Vgat-Mchr1-
KO mice to dopaminergic dysregulation. In order to determine if
MCH acutely inhibits dopamine release, we determined the effect of
MCH (3 mM) on evoked dopamine release in the accumbens of striatal
brain slices. Bath application of 3 mM MCH produced a 25% decrease
in dopamine release that was reversible with the washout of MCH
(Figure 4B). By contrast, MCH did not inhibit dopamine release in
striatal slices produced from Vgat-Mchr1-KO brains (Figure 4B), thus
suggesting that MCH may act via GABAergic MCHR1 neurons to inhibit
dopamine release within the accumbens nucleus.
4. DISCUSSION
Multiple studies have implicated the MCH system in the regulation of
energy homeostasis. Systemic deletion of MCH [8,9] or MCHR1
[15,16,29] in rodents results in increased energy expenditure and
locomotor activity, in part by regulating dopaminergic tone [11]. This
hyperactivity phenotype is also seen following the ablation of MCH
neurons both in early life [20] or adult animals [30]. Consistent with
the role of MCH in suppressing energy expenditure and locomotor
activity, direct chemogenetic activation of these neurons also leads to
decrease spontaneous locomotor activity [31]. The accumbens is a
potential target for MCH action, which additionally includes its effects
on food intake [22,32] and mood [33e35]. However, the identities of
downstream neurons that mediate MCH actions on energy expen-
diture were not well described. In order to identify these neurons, we
used a transgenic model to delete MCHR1 speciﬁcally from
GABAergic neurons marked by the expression of vGAT, which in-
cludes the accumbens. This recapitulated the phenotype following
systemic MCH or MCHR1 deletion, as we observed an increase in
energy expenditure and a two-fold increase in spontaneous loco-
motor activity. An elevated dopaminergic tone contributes to this
hyperactivity, and we localized this effect to the accumbens by site-
speciﬁc MCHR1 deletion.120 MOLECULAR METABOLISM 29 (2019) 114e123  2019 The Authors. Published by Elsevier GmbH. TInterestingly, although MCH has been reported to stimulate food intake
[4,22,23], MCHR1 deletion from vGAT neurons in our studies did not
alter food intake. However, it should be noted that the effects of MCH
on food intake in mice are potentially problematic. While intra-
cerebroventricular (ICV) administration of MCH to rats leads to rapidhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Supplemental Table 1 e Baseline characterization of Mchr1-ﬂox mice
Wildtype (5) Mchr1-ﬂox (5) p value4
Body weight (g)1 19.0  1.0 18.4  1.4 0.749
Food intake (kcal)2 64.0  3.5 66.0  5.7 0.770
Ambulation (counts)3 97,027  9,740 83,083  9,616 0.338
Body weights1, total 6-day ad libitum intake of standard lab chow (3.23 kcal/g)2, and
number of sequential x-axis ambulatory beam breaks over a 24-hour period averaged
over three days3 were determined from eight week old wildtype and homozygous
Mchr1-ﬂox littermates. Numbers and text in parenthesis indicate the number of mice
used and unit of measurement, respectively. All values are reported as group
mean  SEM and compared using an unpaired Student’s t test4.
Supplemental Table 2 e Baseline characterization of Vgat-cre mice
Wildtype (6) Vgat-cre (5) p value4
Body weight (g)1 19.7  0.6 20.0  0.7 0.799
Food intake (kcal)2 62.5  2.8 63.2  3.2 0.855
Ambulation (counts)3 79,915  18,344 80,934  18,585 0.970
Body weights1, total 6-day ad libitum intake of standard lab chow (3.23 kcal/g)2, and
number of sequential x-axis ambulatory beam breaks over a 24-hour period averaged
over three days3 were determined from eight week old wildtype and heterozygous
Vgat-cre littermates. Numbers and text in parenthesis indicate the number of mice
used and unit of measurement, respectively. All values are reported as group
mean  SEM and compared using an unpaired Student’s t test4.and substantive increases in food intake [4,23,36], the effects of ICV
administration in mice is minimal, thus either repetitive or chronic MCH
administration is required to increase food intake [5]. In transgenic
models, global MCH deletion initially decreased food consumption
[8,37], but this effect did not persist over time [9]. Furthermore, in
contrast to MCH deletion, global MCHR1 deletion produces hyper-
phagia [15,16], which was signiﬁcantly more robust in male than fe-
male mice [15]. The absence of a food intake effect in our model could
relate to our use of females [36,38] or to a less robust effect of MCH on
food intake in mice.
Increased locomotor activity is associated with increased dopami-
nergic tone. For example, deletion of the dopamine transporter that
produces a hyperdopaminergic state is associated with spontaneous
locomotor activity [39,40]. Previous reports suggest that MCH is a
regulator of dopaminergic tone. A comparison of accumbens dopamine
release measured using amperometry recordings in ex vivo brain slices
from mice that lack MCH [11] revealed elevated dopamine release
compared to wildtype mice. Similar results were also noted in rats that
lack the MCH peptide precursor [41]. Results from whole animals are
also consistent with increased dopaminergic tone. MCH- and MCHR1-
deﬁcient mice display enhanced sensitization to psychostimulants like
amphetamine [11,17,19] and cocaine [20,42], as well as increased
locomotor responses to the dopamine reuptake blocker GBR12909
[11,20]. We found that in addition to recapitulating the hyperactivity in
global MCH- or MCHR-deﬁcient mice, MCHR1 deletion from vGAT
neurons in our mice also increased dopaminergic tone, and they were
more sensitive to the hyperlocomotor effects of GBR12909.
Since the absence of MCH signaling results in enhanced dopaminergic
tone, MCH itself would have an inhibitory effect on the dopamine
system. Consistent with this, we found that MCH acutely suppressed
dopamine release in accumbens brain slices, an effect that was
abolished following MCHR1 deletion in vGAT neurons. The pathways
downstream of the incumbent GABAergic MCHR1 neurons in the
accumbens that mediate this response have not yet been deﬁned. In
the intact animal, MCH may directly inhibit striatal inputs from dopa-
minergic efferents that originate in the ventral tegmental area or
compact part of the substantia nigra [24,43]. Furthermore, as acti-
vation of vGAT neurons in the ventral tegmental area can suppress
dopamine release in the striatum [44], the loss of the Gi-protein
coupled MCHR1 receptor may disinhibit these neurons and contribute
to the hyperdopaminergic state in our mouse model. Our ﬁndings
conﬁrm that the inhibitory effect of MCH on dopamine release requires
MCHR1 expression on vGAT neurons, thereby identifying for the ﬁrst
time that GABAergic vGAT neurons are key targets of MCH.
Targeting MCHR1 deletion speciﬁcally to the accumbens also
increased spontaneous locomotor activity, thus the accumbens com-
prises a critical GABAergic region underlying the hyperactivity of
MCHR1-deﬁcient mice. The accumbens also mediates the orexigenic
effects of MCH in rats [22,32]. These aggregate data lead us to posit
that the accumbens is a critical component of the neurocircuit that
integrates MCH actions. However, MCHR1 is widely expressed within
the brain, thus site-speciﬁc MCHR1 deletion at other discrete neuro-
anatomical sites would provide additional insights to elucidate the full
range of MCH effects.
5. CONCLUSION
Transgenic models of MCH or MCHR1 deletion produce robust and
consistent effects of increase energy expenditure and locomotor ac-
tivity. While the role of MCH in the regulation of energy homeostasis is
well known, the neuronal population supporting the actions of MCH areMOLECULAR METABOLISM 29 (2019) 114e123  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comnot well deﬁned. We found that MCH acts via a GABAergic neurocircuit
to regulate energy homeostasis. Furthermore, we also show that MCH
regulates dopamine release, and the interaction between dopami-
nergic and GABAergic systems in the accumbens is a critical pathway
contributing to the effects of MCH on energy expenditure.
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